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Background: Heat-shock protein 90 (Hsp90) is vital to cell survival under conditions of stress, and binds client
proteins to assist in protein stabilization, translocation of polypeptides across cell membranes, and recovery of
proteins from aggregates. Therefore, Hsp90 has emerged as an important target for the treatment of cancer.
We previously reported that novel Antp-TPR hybrid peptide, which can inhibit the interaction of Hsp90 with the
TPR2A domain of Hop, induces selective cytotoxic activity to discriminate between normal and cancer cells both
in vitro and in vivo.
Results: In this study, we investigated the functional cancer-cell killing mechanism of Antp-TPR hybrid peptide in
glioblastoma (GB) cell lines. It was demonstrated that Antp-TPR peptide induced effective cytotoxic activity in GB
cells through the loss of Hsp90 client proteins such as p53, Akt, CDK4, and cRaf. Antp-TPR also did not induce the
up-regulation of Hsp70 and Hsp90 proteins, although a small-molecule inhibitor of Hsp90, 17-AAG, induced the
up-regulation of these proteins. It was also found that Antp-TPR peptide increased the endoplasmic reticulum
unfolded protein response, and the cytotoxic activity of this hybrid peptide to GB cells in the endoplasmic
reticulum stress condition.
Conclusion: These results show that targeting of Hsp90 by Antp-TPR could be an attractive approach to selective
cancer-cell killing because no other Hsp90-targeted compounds show selective cytotoxic activity. Antp-TPR might
provide potent and selective therapeutic options for the treatment of cancer.
Keywords: Client proteins, Heat shock protein 90, Hybrid peptide, Molecular chaperone, Unfolded protein
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Malignant gliomas are the most commonly diagnosed
malignant adult primary brain tumors, and median
survival for glioblastoma (GB) is 12–15 months [1].
Targeted therapies, as single agents, have failed to offer
long-term survival benefit, despite objective initial
responses [2]. Heterogeneity and a complex molecular
pathology of GB contribute to the lack of therapeutic
success. It was previously reported that GB cells were
dependent on a range of activated oncoproteins and
signaling pathways which require heat-shock protein 90
(Hsp90) function [3].* Correspondence: kawakami.koji.4e@kyoto-u.ac.jp
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reproduction in any medium, provided the orHsp90 is an abundant cytosolic molecular chaperone
found within multimeric chaperone complexes known to
participate in regulating protein homeostasis in cells. It
is also well known that Hsp90 assists maturation of
more than 200 proteins, which include transmembrane
tyrosine kinase (Her2 and EGFR), metastable signaling
proteins (Akt, K-ras, and Raf-1), mutated signaling
proteins (p53 and v-Src), chimeric signaling proteins
(Bcr-Abl), cell-cycle regulators (Cdk4 and Cdk6), and
steroid receptors (androgen, estrogen, and progesterone
receptors) [4-8]. Therefore, Hsp90 plays a unique role in
cellular homeostasis, and consequently Hsp90 has
emerged as a promising anticancer target.
On the other hand, it is also well known that cells
respond to a wide variety of stresses through the tran-
scriptional activation of genes that harbor stress elementsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that are specific to individual organelles. For example, the
accumulation of misfolded or unfolded proteins in the
endoplasmic reticulum (ER) activate the ER unfolded pro-
tein response (erUPR) [9,10]. The erUPR is a complex
signaling network that enhances cell survival by limiting
the accumulation of unfolded or misfolded proteins in the
ER [9,10]. The erUPR has three signaling pathways –
inositol-requiring 1 (IRE1), PKR-like ER kinase (PERK),
and ER-localized transmembrane protein ATF6 [9,10] –
wherein PERK plays a major role in ER stress-induced
translational attenuation [11]. ATF6 is activated by prote-
olysis and binds in the presence of NF-Y directly to a cis-
acting element (CCAAT-N9-CCACG) to induce ER
stress-inducible proteins which include molecular chaper-
ones [12], whereas IRE1 mediates the unconventional
splicing of XBP1 mRNA, thereby converting it to a potent
erUPR transcriptional activator [13]. These transcription
factors lead to coordinated induction of diverse erUPR
target genes, such as the ER-resident molecular chaper-
ones glucose-regulated proteins 78 (GRP78; also known
as Bip) and 94 (GRP94), for cell survival [14,15]. How-
ever, the erUPR also induces the up-regulation of the
chop gene, encoding a bZIP transcriptional factor CHOP
(C/EBP homology protein), which is regulated by a
number of transcriptional and translational mechanisms
[16]. The induction of CHOP by the erUPR can lead to
the transcriptional activation of Bim, leading in turn to
apoptosis in the case of intolerable levels of the erUPR in
the cells [17]. A broad range of cancer-types rely on ER
protein-folding machinery to correctly fold key signaling
pathway proteins, and erUPRs are strongly induced in
various tumors [18]. Recently, accumulating evidence
has demonstrated that the erUPR is an important mech-
anism required for cancer cells to maintain malignancy
and therapy resistance. Hence, the erUPR may be also
a significant target by which to improve cancer chemo-
therapy [19].
We previously reported that a newly designed Antp-
TPR hybrid peptide inhibits the interaction of Hsp90
with tetratricopeptide repeat 2A domain (TPR2A) of
p60/Hsp-organizing protein (Hop), has selective cyto-
toxic activity that allows it to discriminate between
cancer and normal cell lines, and induces effective anti-
tumor activity in a xenograft model of human pancreatic
cancer in mice [20]. However, the detailed mechanism
of cancer-cell-killing by Antp-TPR peptide still remains
obscure. Recently it was reported that the Hsp90
antagonist geldanamycin and its derivative 17-allylamino-
demethoxygeldanamycin (17-AAG) lead to ER stress-
induced apoptosis in rat histiocytoma [21], whereas it was
also reported that retaspimycin (IPI-504), which is a novel
and soluble type of Hsp90 inhibitor derived from geldana-
mycin, blocks the UPR in multiple myeloma cells [22].It is important for the further elucidation of cancer treat-
ment targeting Hsp90 to address the functional mechan-
ism of cancer-cell killing by Antp-TPR hybrid peptide.
Here we report the mechanisms that Antp-TPR hybrid
peptide uses to induce cancer-cell killing through the
loss of Hsp90 client proteins such as p53, Akt, CDK4,
and cRaf on GB cells. We also show that Antp-TPR
hybrid peptide increases the erUPR and cytotoxic activity
towards GB cells in the erUPR condition.
Results
Cytotoxic activity of Antp-TPR hybrid peptide to GB
cell lines
First we confirmed the previous report by Ohgaki [23]
that the phosphoinositide 3-kinase (PI3K) pathway is
often constitutively active in GB as a result of mutations
and loss of a tumor suppressor, PTEN, compared with
the other cancer cell lines (Additional file 1). Because of
this phenomenon, it is assumed that GB is one of the
most malignant cancers with a very poor prognosis. We
then examined the cytotoxic activity and mechanism of
Antp-TPR peptide in GB cells. As shown in Figure 1A,
addition of Antp-TPR peptide to GB cells (U251, A172,
and SN19) resulted in concentration-dependent cytotox-
icity, and at 50 μM all the cells tested lost their viability.
The IC50 values of Antp-TPR peptide in the GB cell
lines, U251, A172, and SN19 were 26–36 μM, as shown
in Table 1. When we examined the expression levels of
Hsp70, Hsp90, and Akt, which is one of the client pro-
teins of Hsp90 in GB cell lines, it was found that the
endogenous expression levels of these proteins were
equally unremarkable, and that PTEN was lost in these
GB cells compared with the other cancer and normal
cell lines (Figure 1B and Additional file 1).
Cytotoxic mechanism of Antp-TPR in GB cells
We previously demonstrated that Antp-TPR peptide
induced cancer-cell death through the loss of client pro-
teins of Hsp90 such as CDK4 and Akt in breast cancer
T47D cells [20]. These results prompted us to investi-
gate the detailed mechanism of GB cell death as caused
by this peptide. As shown in Figure 2A, treatment of GB
cells (U251, A172, and SN19) with Antp-TPR resulted in
a decrease in the expression of Hsp90 client proteins
including p53, CDK4, Akt, and cRaf, in a concentration-
dependent manner as compared with control untreated
cells. Whereas Antp-TPR did not affect the expression
levels of Hsp90, Hsp70, and Hsp27 proteins in GB cells
after treatment with this peptide, 17-AAG did induce
the up-regulation of these heat-shock proteins (Add-
itional file 2). We next examined the effect of Antp-TPR
on transcriptional level of Hsp90 client proteins (cRaf,
Akt, and CDK4). Interestingly, it was found that the
Antp-TPR peptide almost did not affect the transcription
Figure 1 Cytotoxic activity of Antp-TPR hybrid peptide to GB cells. (A) Viability of GB cells (U251, A172, and SN19) treated with Antp-TPR
peptide. Cells were incubated with Antp-TPR peptide at the indicated concentrations, and analyzed for cell viability as described in the Materials
and Methods section. Data represent the mean ± SD from experiments performed in triplicate. (B) Analysis of Hsp90, Hsp70, PTEN, and Akt
expression in GB and normal cell lines. Cell extracts from the indicated GB and normal PE (ACBRI 515) cell lines were examined for Hsp90, Hsp70,
PTEN, and Akt expression by Western-blot analysis with corresponding antibodies. β-Actin was used as the loading control. Bands were visualized
by chemiluminescence as described in the Materials and Methods section.
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decreased the levels of mRNA for these proteins except
for the levels of cRaf and Akt in U251 cells at higher
concentrations (80 μM) (Figure 2B). These results indi-
cate that Antp-TPR induces the loss of Hsp90 client pro-
teins through the degradation of both protein and
mRNA levels in GB cells. In addition, it was also found
that the treatment of GB cells with Antp-TPR did not
activate the Erk pathway, which is important for the dif-
ferentiation and proliferation of cancer cells (Figure 2C).
Molecular diversity of the cancer-cell-killing mechanism
of Antp-TPR peptide and 17-AAG
The rate of Antp-TPR hybrid peptide-mediated cancer-
cell killing was further investigated. A 6 h exposure of
U251 and A172 cells to Antp-TPR (50 μM) was suffi-
cient to induce high levels of cytotoxic activity to kill
cells (approximately 70-80% decrease in cell viability)
(Figure 3A). And, the decrease of cell viability with
time dependent manner was not found in normal PE
cells after the treatment with Antp-TPR (Figure 3A). In
contrast, treatment with 17-AAG did not substantially
affect cell viability, even after 24 h of treatment; how-
ever, a 48 h exposure of GB cells to 17-AAG resulted
in an approximately 40–50% decrease in cell viability
(Additional file 3A). It is known that the treatment ofTable 1 Inhibitory concentration (IC50) of Antp-TPR
peptide of glioma cells
Cell line IC50 (μM)
*
SN19 26.53 ± 5.78
A172 28.27 ± 7.23
U251 35.70 ± 0.92
*Results are the mean of three independent experiments and each
performed in triplicate.cancer cells with 17-AAG induces the up-regulation of
Hsp70, and it is suggested that compensatory up-
regulation of this protein is likely to correlate with the
decrease of anticancer activity [24,25]. As shown in
Figure 3B, 0.5 μM of 17-AAG quickly induced the up-
regulation of Hsp70 within 6 h of treating U251, A172,
and SN19 cells with this compound, whereas Antp-TPR
did not cause the up-regulation of Hsp70 and Hsp90
proteins (Figure 3B). The up-regulation of these heat-
shock proteins (Hsp90, Hsp70, and Hsp27) in GB cells
by 17-AAG was also confirmed in transcriptional levels
of mRNA, and Antp-TPR did not almost affect the tran-
scriptional levels of these proteins (Figure 3C). In
addition, the cytotoxic activity of Antp-TPR to U251
cells was not affected in the presence of PES, which was
identified recently as a Hsp70 inhibitor by Leu et al.
[26,27], although the cytotoxic activity of 17-AAG was
increased in this condition (Additional file 3B). These
results suggest that the Antp-TPR hybrid peptide has a
different cancer-cell-killing mechanism than 17-AAG,
and so might have an additional advantage compared
with other Hsp90-targeted small compounds.
Increase of the erUPR by Antp-TPR peptide in GB cells
It was previously reported that 17-AAG induced the
erUPR in rat histiocytoma [21], and in the current study
we found that Antp-TPR has a different mechanism of
action for cancer-cell killing compared with the conven-
tional small-compound inhibitors targeting Hsp90
(Figure 3B and C). These evidences prompted us to in-
vestigate the action of this peptide in GB cells in relation
to the erUPR. Thus, we next examined the effect of
Antp-TPR on the erUPR in GB cells (U251, A172, and
SN19). As shown in Figure 4A, it was found that Antp-
TPR also increased the activation of Bip promoter
Figure 2 Loss of Hsp90 client proteins. (A) GB cells (U251, A172, and SN19) were treated with or without Antp-TPR peptide at the indicated
concentrations, and examined by Western-blot analysis for expression of Hsp90, Hsp70, Hsp27, p53, CDK4, Akt, cRaf, and β-actin using
corresponding antibodies. (B) Effect of Antp-TPR peptide on the transcriptional level of Hsp90 client proteins. Total RNA isolated from GB cells
treated with or without Antp-TPR peptide at the indicated concentrations were reverse transcribed to cDNA, and then assessed by PCR (inset)
or real-time quantitative PCR using specific primers as described in the Materials and Methods section. GAPDH served as an internal control.
(C) Effect of Antp-TPR peptide on the Erk1/2 pathway. GB cells were treated with or without Antp-TPR peptide as indicated, and examined by
Western-blot analysis for expression of PI3K, Erk1/2, or phosphorylated (p-) Erk1/2 using corresponding antibodies. β-Actin was used as the
loading control. All bands of the Western-blot analysis were visualized by chemiluminescence.
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the reporter gene plasmid pBipPro-Luc [28] after induc-
tion of the erUPR by Thapsigargin (Tg), which induces
the depletion of Ca2+ in the ER. And a similar result was
found with 17-AAG in GB cells except for A172 cells.
This increase in the activation of Bip promoter activity
by Antp-TPR was also found in the erUPR condition
induced by tunicamycin (data not shown). In addition,
Antp-TPR increased the transcriptional levels of Bip
and CHOP after induction of the erUPR in GB cells
(Figure 4B). On the other hand, the promoter activity of
YME1L1 and GCP60, which are the respective mtUPR
and Golgi apparatus stress responsive genes, as described
previously [28,29], were not increased by Antp-TPR after
the induction of mtUPR or Golgi stress (Additional file4A). These results indicate that treatment with Antp-
TPR peptide increases the erUPR specifically in GB cells.
When we examined the effect of Antp-TPR on the ex-
pression level of Bim after induction of the erUPR in GB
cells, it was found that the up-regulation of Bim after
erUPR induction was not dramatically increased by treat-
ment with Antp-TPR in this condition (Figure 4C).
Increase of cytotoxic activity of Antp-TPR peptide
in the erUPR
We next characterized Antp-TPR peptide-induced cyto-
toxicity in GB cells after induction of the erUPR. As
shown in Figure 5A, the treatment of GB cells with
Antp-TPR increased the population of annexin-positive
cells in the erUPR condition; however, 17-AAG did not
Figure 3 Molecular diversity of the cancer-cell-killing mechanism of Antp-TPR peptide and 17-AAG. (A) Time course of cell viability after
the treatment with Antp-TPR peptide. GB (U251, A172, and SN19) and normal PE (ACBRI 515) cells were treated with Antp-TPR at the indicated
concentrations, and then analyzed for cell viability by WST-8 assay. Data represent the mean ± SD from experiments performed in triplicate.
(B) Induction of Hsp70 and Hsp90 by 17-AAG. GB cells were incubated with or without Antp-TPR peptide or 17-AAG for the indicated times, and
extracts were examined by Western-blot analysis for expression of Hsp90, Hsp70, and Akt with their corresponding antibodies. β-Actin was used
as the loading control. Bands were visualized by chemiluminescence. (C) Effect of Antp-TPR peptide and 17-AAG on transcription levels of Hsp27,
Hsp70, and Hsp90 proteins. Total RNA isolated from GB cells treated with or without Antp-TPR peptide or 17-AAG at the indicated concentrations
and time were reverse transcribed to cDNA, and then assessed by PCR (inset) or real-time quantitative PCR using specific primers as described in
the Materials and Methods section. GAPDH served as an internal control.
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itional file 4B). When we examined the cytotoxic activity
of Antp-TPR peptide towards GB cells in the erUPR
condition, interestingly, it was found that Antp-TPR
caused the elevation of cytotoxic activity against GB
cells tested in this study, but 17-AAG did not show an
increase in cytotoxic activity toward GB cells under the
conditions (Figure 5B). In addition, neither Antp-TPR
nor 17-AAG increased the cytotoxic activity toward nor-
mal PE cells (ACBRI 515) in the erUPR condition with
concentration-dependent manner (Figure 5B). When we
examined the effect of Antp-TPR on mitochondrial
membrane potential after induction of the erUPR in GB
cells, it was found that treatment with Antp-TPR did
not dramatically alter disruption of the mitochondrialmembrane potential by the erUPR (Figure 5C), and 17-
AAG also did not affect the mitochondrial membrane
potential after induction of the erUPR (Additional
file 4C). These results indicate that Antp-TPR peptide
has selective cytotoxic activity that allows it to discrim-
inate between cancer and normal cell lines, and that it
induces an increase of this activity against cancer cells in
the erUPR condition.
Discussion
In this study we have shown that global subcellular tar-
geting of the Hsp90 network with Antp-TPR hybrid
peptide provides effective cytotoxic activity against GB
cells (U251, A172, and SN19). It was found that Antp-
TPR peptide mechanistically induced a simultaneous
Figure 4 Increase of the erUPR by Antp-TPR peptide. (A) The increase of Bip promoter activation by either Antp-TPR peptide or 17-AAG.
GB cells (U251, A172, and SN19) were transfected with pBipPro-Luc and exposed to ER stress. Cells were incubated with or without Antp-TPR
peptide or 17-AAG for 18 h after 1 h of treatment with Tg, and then a reporter assay was performed using the Dual-Glo Luciferase assay system
as described in the Materials and Methods section. Data represent the mean ± SD (*P < 0.01 compared to control cells without Antp-TPR or
17-AAG). (B) Effect of Antp-TPR peptide on the transcriptional level of Bip and CHOP after induction of the erUPR. Total RNA isolated from GB
cells treated with or without Antp-TPR peptide after the induction of the erUPR by Tg treatment was reverse-transcribed to cDNA, and then
assessed by PCR (inset) or real-time quantitative PCR using specific primers for Bip and CHOP as described in the Materials and Methods section.
GAPDH served as an internal control. Histogram represent the mean ± SD (*P < 0.01 and **P < 0.05 compared to Tg+Antp-TPR 0 μM group,
respectively). (C) Effect of Antp-TPR peptide on expression level of Bim after induction of the erUPR. GB cells were treated with or without
Antp-TPR peptide after induction of the erUPR by Tg treatment, and then examined by Western-blot analysis to determine the expression level
of Bim. Bands were visualized by chemiluminescence and β-actin was used as the loading control.
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p53, CDK4, Akt, and cRaf in the cytosol, triggering
cancer-cell killing. GB cells are dependent on a range
of activated oncoproteins and signaling pathways that
require Hsp90 function [3]. Thus, Hsp90 inhibitors have
been interesting agents with which to improve treatment
results in GB, a primary brain tumor with a particularlydismal prognosis [30]. Although Hsp90-based therapy
has been intensely pursued as a paradigm of network-
oriented drug discovery [31-33], the clinical results by
these agents have so far been inferior to expectations,
producing only small gains in cancer patients [33]. In
this study we found that the molecular activity of Antp-
TPR is diverse from 17-AAG in its cancer-cell-killing
Figure 5 Characterization of Antp-TPR peptide-induced GB cell killing after induction of the erUPR. (A) Multiparametric flow cytometry.
GB cells (U251, A172, and SN19) were incubated with or without Antp-TPR peptide for 18 h in the presence or absence of 0.1 μM Tg, and
analyzed for annexin and propidium iodide (PI) staining. (B) The increase of cytotoxic activity of Antp-TPR peptide in the erUPR condition. GB and
normal PE (ACBRI 515) cells were incubated with or without Antp-TPR peptide or 17-AAG (inset graph) at the indicated concentrations for 24 h
in the presence or absence of Tg (0.05 μM), and cytotoxic activity was determined by WST-8 assay as described in the Materials and Methods
section. Data represent the mean ± SD from experiments performed in triplicate. The single and double asterisks indicate P<0.01 and P< 0.05,
respectively. (C) Mitochondrial membrane potential. After treatment with or without Antp-TPR peptide in the presence or absence of Tg, GB cells
were labeled with the mitochondrial transmembrane potential-sensitive fluorescent dye JC-1, and then images were taken using confocal laser
scanning microscope as described in the Materials and Methods section. All scale bars are 50 μm.
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In addition, Antp-TPR peptide did not cause the up-
regulation of Hsp27, Hsp70, and Hsp90 proteins after
treatment with this peptide (Figures 2 and 3). It was pre-
viously reported that the conventional Hsp90 ATPase
inhibitors induce a compensatory up-regulation of
Hsp70 that likely correlates with the decrease of antican-
cer activity [24,25]. It was also reported that 17-AAG
induces the up-regulation of Hsp27, elevation of gluta-
thione concentration, and resistance to this compound
through a glutathione-mediated mechanism in cancer
cells [34]. We also found that Antp-TPR peptide did not
increase the concentrations of glutathione after treat-
ment with this peptide in cancer cells (data not shown).
Taking together this evidence and the results of ourstudy, Antp-TPR hybrid peptide might have an add-
itional advantage over Hsp90-targeted small compounds
such as geldanamycin and 17-AAG.
Recently, Saito et al. [35] reported that the antidiabetic
biguanides metformin, buformin, and phenformin could
work as erUPR modulators during glucose deprivation
in cancer cells, and that disrupting the erUPR could be
an attractive approach for selective cancer-cell killing.
Meanwhile, depending on the type of tumor, compounds
which induce and increase the erUPR can also be used
as anticancer agents such as the proteasome inhibitor
bortezomib or the Hsp90 inhibitors geldanamycin and
17-AAG [36,37]. In this study, it was also found that
Antp-TPR increased the erUPR through both activation
of Bip promoter and up-regulation of transcriptional
Horibe et al. Molecular Cancer 2012, 11:59 Page 8 of 11
http://www.molecular-cancer.com/content/11/1/59levels of Bip and CHOP, and then elevated the cytotoxic
activity against GB cells (Figures 4 and 5). Since the
Antp-TPR peptide did not increase the promoter activity
of YME1L1 and GCP60 after induction of the mtUPR
and Golgi stress (Additional file 4A), it is suggested that
Antp-TPR might affect the erUPR specifically in cancer
cells. In addition, Antp-TPR peptide did not increase
cytotoxic activity against normal cells even in the erUPR
condition (Figure 5). Interestingly, although 17-AAG
also increased activation of the Bip promoter, the effect-
ive enhancement of the cytotoxic activity to GB cells by
this compound was not observed (Figures 4 and 5).
Thus, it is possible that Hsp proteins such as Hsp70 and
Hsp90, up-regulated by the treatment of 17-AAG, might
prevent the enhancement of cytotoxic activity against
GB cells even during the erUPR.
It is well known that cancer cells are often exposed
to hypoxia, nutrient starvation, oxidative stress, and
other types of metabolic dysregulation that cause ER
stress and activation of the erUPR. Depending on the
duration and degree of ER stress, the erUPR can provide
either survival signals by activating adaptive and antia-
poptotic pathways or death signals by inducing a cell-
death program. Sustained induction or repression of
erUPR pharmacologically may thus have beneficial and
therapeutic effects against cancer. In fact, glucose
deprivation as well as hypoxia are common features in
poorly vascularized solid tumor but are not observed in
normal tissue. Interestingly, since Antp-TPR peptide
increased cytotoxic activity against cancer cells after in-
duction of the erUPR it is expected that it might exert
effective antitumor activity if it penetrates a tumor.
Although it is suggested that peptides are relatively
easily inactivated by serum components in the human
body, there are currently many candidate anticancer
peptides which target intracellular molecules or orga-
nelles [38,39]. In fact, we previously reported that a
1 mg/kg dosage of Antp-TPR peptide displayed a signifi-
cant antitumor activity in a xenograft model of human
pancreatic cancer in mice [20]. This dosage of Antp-TPR
in vivo is supposed to be lower than the concentrations
estimated from IC50 values tested in vitro compared with
small compounds such as 17-AAG. As mentioned above,
Antp-TPR may have an advantage over small com-
pounds in terms of effective antitumor activity.
Conclusion
Our current data describe how Antp-TPR has the
molecular features of a novel class of global Hsp90
inhibitor, which is capable of simultaneously disabling
the multiple pools of client proteins to increase the
erUPR in cancer cells. Such an approach might offer
a new therapeutic approach for the management of
heterogeneous and otherwise malignant human tumors,including GB. Taken together with our previous study
[20], Antp-TPR hybrid peptide may provide a potent
and novel type of selective anticancer therapy through
its action as an erUPR modulator. Thus, the findings of




Anti-Hsp90, anti-Hsp70, and anti-Hsp27 antibodies were
purchased from Stressgen Bioreagents (Ann Arbor, MI,
USA). Anti-c-Raf, anti-Akt, andCDK4 antibodies were pur-
chased from Cell Signaling (Danvers, MA, USA). Anti-p-53
and anti-βactin antibodies, and 2-phenylethynesulfonamide
(PES; also called pifithrin-μ) were purchased from Sigma
(St Louis, MO, USA). 17-AAG was purchased from Invivo-
Gen (San Diego, CA, USA). Thapsigargin (Tg), tunicamy-
cin, and other reagents were mostly obtained from Nacalai
Tesque (Kyoto, Japan). All reagents were of reagent grade.
Cells and cell culture
Human GB cell lines (A172 and SN19) were purchased
from the American Type Culture Collection (ATCC,
Manassas, VA, USA), and U251 cell line was obtained
from the National Cancer Institute, Frederick Cancer
Research Facility, Division of Cancer Treatment Tumor
Repository Program (Frederick, MD, USA). The normal
pancreatic epithelial (PE) cell line ACBRI 515 was pur-
chased from the European Collection of Cell Culture
(ECACC, Salisbury, UK). Cells were cultured in RPMI-
1640 (U251, A172, and SN19 cells) or CSC (ACBRI 515
cells) containing 10% fetal bovine serum, 100 μg/ml
penicillin, and 100 μg/ml streptomycin at 37°C and in an
atmosphere of 5% CO2/95% air.
Peptide synthesis
Peptides used in this study were synthesized by the
American Peptide Company (Sunnyvale, CA, USA).
Peptides were dissolved in water and buffered to pH 7.4
as described previously [20]. The TPR sequence 301 K-
312 K (KAYARIGNSYFK; TPR) [20] was made cell-
permeable by addition of helix III of the cell-penetrating
Antennapedia homeodomain sequence (underlined)
[40], as follows: RQIKIWFQNRRMKWKKKAYARIGN
SYFK (Antp-TPR).
Western blotting
Western blot analyses were carried out as described pre-
viously [20,41]. Briefly, protein extracts were prepared
from cells lysed with buffer containing 1% (v/v) Triton
X-100, 0.1% (w/v) SDS, and 0.5% (w/v) sodium deoxy-
cholate, separated by SDS-PAGE and transferred to
nitrocellulose filters by iBlot system (Invitrogen, Carls-
bad, CA, USA) according to the manufacturer’s protocol.
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analyzed using enhanced chemiluminescence reagent
(GE Healthcare Bioscience, Uppsala, Sweden) with a LAS-
3000 LuminoImage analyzer (Fujifilm, Tokyo, Japan).
RT-PCR
The total RNA in cells was isolated using the NucleoS-
pin RNA kit (Macherey-Nagel, Düren, Germany). For
RT reactions 0.5 μg of RNA sample was used, and the
reaction was performed in a final volume of 10 μl of re-
action mixture using the ReverTraAce RT kit
(TOYOBO, Osaka, Japan). Each 1 μl aliquot of cDNA
was amplified in a final volume of 50 μl of PCR mixture.


















30. GAPDH was used as an internal control.
PCR product was run on a 1% agarose gel for
UV analysis.
Quantitative real-time PCR analysis
Quantitative real-time PCR analysis was carried out
using the SYBR Green Real-time PCR Master Mix kit
(TOYOBO) on the Mx3000p Real-time QPCR System
(Stratagene, La Jolla, CA, USA). Amplification was per-
formed under the following conditions: after an initial
denaturation step of 95°C for 60 s: 45 cycles of 95°C for
15 s, 60°C for 15 s, and 72°C for 45 s. The primers were
the same as for RT-PCR analysis (see previous section).
Assay for cell viability
Cell viability was determined by WST-8 assay as
described previously [20]. Briefly, cells were seeded onto
96-well plates at 2000–3000 cells/well. After incubating
with the test peptides, the assay for cell viability was car-
ried out using Living Cell Count Reagent SF (Nacalai
Tesque) according to the manufacturer’s protocol. Ab-
sorbance was measured at a wavelength of 450 nm using
a 96-well microplate reader (GE Healthcare Bioscience).Cytotoxic activity was calculated from the percentage of
cell viability; 0% cell viability was defined as 100% cyto-
toxic activity (100% cell-killing activity).
Reporter assay
A reporter assay was carried out as described previously
[35]. Briefly, GB cells (U251, A172, and SN19) were trans-
fected with firefly luciferase-containing reporter plasmids
of the Bip promoter (pBipPro-Luc), in which the Bip pro-
moter region was cloned as described previously [28].
The Renilla luciferase-containing plasmid pRL-SV40
(Promega, Madison, WI, USA) was used as an internal
control. The relative activity of firefly luciferase to Renilla
luciferase (mean ± SD from triplicate determinations) was
determined using the Dual-Glo Luciferase Assay System
(Promega). 0.05-0.5 μM of Tg was used for the induction
of erUPR depend on the number of cells. Induction of
mitochondrial UPR (mtUPR) and Golgi apparatus stress
was carried out as described previously [28,29].
Flow cytometry assay
Flow cytometry assay was performed as described previ-
ously [20,42]. Briefly, after incubation with or without
Antp-TPR peptide or Tg, cells were collected and
washed twice with PBS. Following this, the cell pellets
were resuspended. Flow cytometry (Becton Dickinson)
analysis was performed using the Annexin V-Fluorescein
Staining Kit (Wako) according to the manufacturer’s
protocol. Data were analyzed using CellQuest Software.
Analysis of mitochondrial membrane potential
Change of mitochondrial membrane potential was evalu-
ated as described previously [43]. Briefly, cells were
labeled for 30 min with 5 μg/ml mitochondrial mem-
brane potential-sensitive fluorescent dye, JC-1 (Invitrogen,
Carlsbad, CA, USA), in a glass-bottomed dish after treat-
ment with or without Antp-TPR or Tg, and then confocal
images were taken using an Olympus FV 1000 confocal
laser scanning microscope (Olympus, Tokyo, Japan).
Statistical analysis
All values are expressed as the mean ± SD and statistical
significance was determined using the Student t-test
with statistical significance assessed with a probability
value less than 0.05.
Additional files
Additional file 1: Analysis of PTEN expression in human breast
(BT20 and T47D), lung (H460, A549, H322, and H1299), colon
(COLO320HSR), and prostate (DU145) cancer, epithelial carcinoma
(A431), and GB (U251) cell lines. Cell extracts from the indicated cell
lines were examined for PTEN expression by Western-blot analysis with
antibodies against PTEN. β-Actin was used as the loading control. Bands
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Methods section.
Additional file 2: Effect of 17-AAG on Hsp90, Hsp70, Hsp27, and
Akt expression in GB cells. A172 cells were treated with different
concentrations of 17-AAG for 24 h. After 24 h cells were harvested and
examined for Hsp90, Hsp70, Hsp27, and Akt expression by Western-blot
analysis with antibodies against these proteins. β-Actin was used as the
loading control.
Additional file 3: Time course of cell viability after treatment with
Antp-TPR or 17-AAG (A) and effect of Hsp70 inhibitor on the
cytotoxic activity of Antp-TPR or 17-AAG to U251 cells (B). (A) U251
cells were treated with Antp-TPR or 17-AAG at the indicated
concentrations, and then analyzed for cell viability by WST-8 assay. (B)
U251 cells were treated with Antp-TPR or 17-AAG at the indicated
concentrations in the presence or absence of PES (2.5 μM), and then cell
viability was assessed by WST-8 assay. Data represent the mean ± SD.
Additional file 4: Effect of Antp-TPR peptide on up-regulation of
the YME1L1 and GCP60 genes under the mtUPR or Golgi stress
condition (A) and Characterization of 17-AAG-induced GB cell killing
after induction of the erUPR (B and C). (A) U251 cells were transfected
with YME1L1 and GCP promoter-reporter constructs and exposed to
mitochondrial or Golgi stress as described in the Materials and Methods
section. After induction of mtUPR or Golgi stress, cells were incubated
with or without Antp-TPR peptide for 18 h, and then reporter assay was
performed by the Dual-Glo Luciferase assay system. Data represent the
mean ± SD. (B) Multiparametric flow cytometry. U251 cells were
incubated with or without 17-AAG peptide for 18 h in the presence or
absence of 0.5 μM Tg, and analyzed for annexin and propidium iodide
(PI) staining. (C) Mitochondrial membrane potential after treatment with
17-AAG. After treatment with or without 17-AAG in the presence or
absence of Tg, U251 cells were labeled with JC-1 and then images were
taken using a confocal laser scanning microscope as described in the
Materials and Methods section. All scale bars are 50 μm.
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